Clinical trial · Observational
Cognitive Function After Radiation Therapy for Brain Tumours
NCT04118426CI-TRIAL-00041085WP-12-precompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study will assess cognitive function in adult patients with a primary brain tumour treated with surgical resection with or without radiation therapy (RT). All types of brain tumours apart from glioblastoma will be included
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Primary Brain Tumor | Primary Brain Tumor | ONTOLOGY_EXACT | 0.98 |
| Radiation Toxicity | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Cognitive testing | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Radiotherapy group
- description
- Patients receiving radiotherapy after surgery for brain tumor
- interventionNames
- Radiation: Cognitive testing
- label
- No radiotherapy group
- description
- Patients NOT receiving radiotherapy after surgery for brain tumor
- interventionNames
- Radiation: Cognitive testing
Primary outcomes (2)
- measure
- Memory impairment (as assessed by the HVLT-r)
- timeFrame
- 1-10 years after treatment
- description
- To examine the correlation between memory impairment (assessed by HVLT-r) and mean dose to the hippocampus.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 100 Years
Show eligibility criteria text
Inclusion Criteria:
* The participant must be 18 years or older and Danish speaking.
* Performance status 0-2
* Capable of cooperating on testing
* Diagnosed with one of the following diagnoses according to WHO 2016 classification 16 and been treated between 2006 and 2016
1. ZM93803 glioma (exclusive glioblastoma)
2. ZM9401/3 anaplastic astrocytoma, IDH mutant
3. ZM9400/3 diffuse astrocytoma, IDH-mutant
4. ZM9411/3 gemistocytisk astrocytoma, IDH mutant
5. ZM9400/3 diffuse astrocytoma, NOS
6. ZM9451/3 anaplastic oligodendroglioma, IDH mutant and 1p/19q-co deleted
7. ZM9450/3 oligodendroglioma, IDH mutant and 1p/19q-co deleted
8. ZM9450/3 oligodendroglioma, NOS
9. ZM9451/3 anaplastic oligodendroglioma, NOS
10. ZM9530/0 meningioma
11. ZM9470/3 medulloblastoma, NOS
12. DD352A pituitary adenoma
13. Other rare brain tumours including skull base sarcomas
\-
Exclusion Criteria:
Performance status 3-4 Progression after radiation therapy
\-References
Publications (1)
- DERIVEDHaldbo-Classen L, Amidi A, Lukacova S, Wu LM, Oettingen GV, Lassen-Ramshad Y, Zachariae R, Kallehauge JF, Hoyer M. Cognitive impairment following radiation to hippocampus and other brain structures in adults with primary brain tumours. Radiother Oncol. 2020 Jul;148:1-7. doi: 10.1016/j.radonc.2020.03.023. Epub 2020 Mar 28. PMID 32298906